Skip to main content
. 2022 Jun 30;108(1):110–121. doi: 10.3324/haematol.2022.280805

Figure 2.

Figure 2.

Progression-free survival and overall survival from CAR T-cell infusion stratified by prognostic factors. (A) Progression-free survival (PFS) by disease status at lym-phodepletion. (B) PFS by lactate dehydrogenase (LDH) at leukapheresis. (C) PFS by LDH at lymphodepletion. (D) Overall survival (OS) by LDH at leukapheresis. (E) OS by Eastern Cooperative Group performance status (ECOG PS) at lymphodepletion.